Amidst a surge in clinical studies delving into the transformative potential of psychedelic drugs, an intriguing paradox has emerged within the market dynamics – a notable disparity between the expanding realm of scientific exploration and the lagging valuations of companies operating in the psychedelic sector.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…